Search the Newsreel

Maximus (MMS) Stock Looks Reasonable Following Its 32% YTD Decline

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Maximus has had a difficult start to the year, with the share price down 31.5% year to date. However, valuation checks suggest the …

Yimutian Inc (YMT) Stock News Today

This article from TradingKey provides current stock information for Yimutian Inc (YMT), noting its recent trading price of $0.347 with a slight decrease of 1.17%. The page serves as a hub for news, analysis, and financial data for YMT, though it indicates that more …

Yimutian Inc (YMT) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Yimutian Inc (YMT), detailing future EPS and revenue growth estimates. It includes a snapshot of the company's current stock performance, market capitalization, and various financial metrics. The report also lists a peer comparison of other software and …

Replimune Group Inc (REPL) Earnings Forecast: Future EPS & Revenue Growth Estimates

Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.

Replimune secures FDA approval for Tudriqev on its third attempt, making it the company’s first product on the market. Continue Reading

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. (REPL)

NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities who purchased or otherwise …

REPL INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Replimune Group Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

ATLANTA, Aug. 07, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Replimune Group, Inc. (“Replimune”) (NASDAQ: REPL). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information, including allegations that: (1) …

FMR LLC discloses 10.6% Maximus Inc (MMS) ownership in amended 13G

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a 10.6% beneficial ownership in Maximus Inc (MMS) common stock as of June 30, 2026. This equates to 5,544,431.76 shares, with FMR LLC holding sole voting power over 4,624,665.54 shares and …

Maximus Q3 Earnings Beat Estimates, Increase Year Over Year

Maximus (MMS) reported mixed third-quarter fiscal 2026 results, with earnings beating estimates but revenues falling short. The company's adjusted earnings per share increased year-over-year, despite a decline in overall revenues due to factors like reduced natural disaster support and temporary clinical volume surges in …

Replimune Group Inc (REPL) Stock News Today

Simulations Plus, Inc. (SLP) Stock Analysis: Evaluating the Healthcare Software Specialist with 7.5% Revenue Growth

Maximus, Inc. $MMS Stock Position Lifted by Quantinno Capital Management LP

Quantinno Capital Management LP significantly increased its stake in Maximus, Inc. by 413.1% in the first quarter, now holding 76,181 shares valued at approximately $4.9 million. This move comes as institutional investors collectively own 97.21% of the company. Maximus reported strong quarterly earnings of …

Maximus Q3 FY26 slides: margins expand but guidance cut on VA contract

Maximus (NYSE: MMS) reported Q3 FY26 results with margin expansion and an EPS beat, but cut its full-year profit outlook due to a temporary contractual modification with a major federal customer, causing its stock to drop by 10.85%. Despite the guidance cut, the company …

Replimune Wins FDA Accelerated Nod For TUDRIQEVTM In Advanced Melanoma

(RTTNews) - Replimune Group, Inc. (REPL) announced that the U.S. FDA has granted accelerated approval for TUDRIQEVTM, in combination with Nivolumab (Bristol Myers Squibb), for adults with unresectable advanced cutaneous melanoma who have progressed following anti-PD-1 antibody-based therapy. Advanced melanoma patients often face limited …

Stockholder Alert: Robbins LLP Informs Investors of the Replimune Group, Inc. Class Action

Robbins LLP has filed a class action lawsuit against Replimune Group, Inc. on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune misled investors regarding the efficacy of its lead product candidate, RP1, particularly …

Replimune Group, Inc. (REPL) Stock Price, News, Quote & History

This article provides comprehensive information on Replimune Group, Inc. (REPL), a clinical-stage biotechnology company focused on cancer immunotherapies. It includes current stock price, historical performance data, financial overview, analyst insights, and comparisons with similar companies. The stock showed an 8.71% increase at close on …

Is Maximus (MMS) Undervalued Following Mixed Q3 Earnings And Lower End Guidance?

Replimune gains accelerated approval of Tudriqev for cutaneous melanoma

[Dermoscopic image of malignant melanoma skin tumor] Izzet Esmece/iStock via Getty Images * The US FDA has granted accelerated approval to Replimune's (REPL [https://seekingalpha.com/symbol/REPL]) gene therapy Tudriqev (vusolimogene oderparepvec) in combination with Bristol Myers Squibb's (BMY [https://seekingalpha.com/symbol/BMY]) Opdivo (nivolumab) as a second-line treatment for …

Replimune Group (REPL): Montanova-affiliated investors report over 7% ownership

Montanova Capital, LLC and affiliated investors, including Aaron Cowen, have reported a significant ownership stake in Replimune Group, Inc. (REPL) via a Schedule 13G/A filing. Montanova Capital and Aaron Cowen each beneficially own 7.9% of Replimune's common stock, while Averill Master Fund, Ltd. holds …

FDA Approves Replimune’s Melanoma Drug on Third Attempt

The FDA has approved Replimune Group's melanoma drug, Tudriqev, after two prior rejections due to clinical data quality concerns. Tudriqev is a genetically modified virus injected into tumors to kill cancer cells and activate an immune response. This approval marks the end of a …

MaxHP to advance human performance for the modern warfighter

Maximus and Endurion have launched MaxHP, a strategic joint venture designed to optimize human performance for the United States Special Operations Command (USSOCOM) Enterprise. MaxHP aims to support warfighters and their families by integrating physical, cognitive, and behavioral readiness through embedded practitioners who understand …

US FDA approves Replimune's skin cancer drug after prior rejections

The U.S. FDA has approved Replimune's drug Tudriqev, in combination with Bristol Myers Squibb's Opdivo, for a difficult-to-treat form of advanced melanoma. This approval marks Replimune's first marketed product after previous rejections, and the drug will compete with Iovance Biotherapeutics' Amtagvi. The decision was …

Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen

Replimune announced that the FDA has granted accelerated approval for TUDRIQEVTM (vusolimogene oderparepvec-wtpg) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma who have progressed on anti-PD-1 therapy. This approval is based on objective response rate and duration of response from the …

Melanoma therapy after anti-PD-1 progression gets FDA accelerated approval

Replimune announced that the FDA has granted accelerated approval for TUDRIQEV in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that has progressed on anti-PD-1 therapy. This approval is based on results from the Phase 1/2 IGNYTE trial, showing a 24.2% objective …

Earnings Flash (MMS) Maximus, Inc. Reports Q3 Revenue $1.28B, Vs. FactSet Est of $1.33B

Maximus, Inc. (MMS) announced its Q3 revenue, reporting $1.28 billion, which fell short of FactSet's estimate of $1.33 billion. This earnings flash provides key financial figures for the company's recent quarter.

Did Maximus (NYSE:MMS) Revenue Miss Weigh on Shares?

MAXIMUS, INC. 2026: Revenue $1.28B, EPS $1.95— 10-Q Summary

MAXIMUS, INC. (MMS) reported its Q2 2026 results, showing revenue of $1.28 billion, a 5.1% decrease year-over-year, and diluted EPS of $1.95, an increase of 4.8%. The revenue decline was primarily due to lower volumes in transaction-based contracts and reduced short-term disaster work, while …

Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

Johnson Fistel, PLLP is investigating Simulations Plus, Inc. (NASDAQ: SLP) after the company cut its fiscal 2025 revenue guidance and disclosed significant accounting issues. The investigation follows a substantial decline in Simulations Plus's share price after these announcements, including a $77.2 million non-cash impairment …

First Eagle Investment Management (SLP) reports 5.30% beneficial stake in Simulations Plus

First Eagle Investment Management, LLC has reported a beneficial ownership of 5.30% in Simulations Plus Inc., totaling 4,674,801.24 shares. The firm acts as an investment adviser for various clients, holding sole voting and dispositive power over 1,070,582 shares. This disclosure, filed under SCHEDULE 13G, …

[10-Q] MAXIMUS, INC. Quarterly Earnings Report

Earnings call transcript: Maximus cuts FY2026 profit outlook as shares fall in Q3

Is Optimum Communications Inc (OPTU) Worth Considering After Q2

Optimum Communications, Inc. (OPTU) Reports Q2 Loss, Misses Revenue Estimates

Maximus (NYSE:MMS) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings

Maximus (NYSE:MMS) reported Q2 CY2026 sales of $1.28 billion, missing Wall Street estimates and representing a 5.1% year-on-year decline. Despite the revenue miss, the company's non-GAAP profit of $2.22 per share slightly beat consensus estimates. Maximus reconfirmed its full-year revenue guidance but lowered its …

Maximus Reports Fiscal Year 2026 Third Quarter Results

Maximus (NYSE: MMS) reported its fiscal year 2026 third-quarter results, showing strong earnings despite a slight revenue dip compared to the prior year. The company reiterated its full-year revenue guidance but updated its earnings and free cash flow guidance due to a temporary contractual …

Optimum Communications (NYSE:OPTU) Misses Q2 CY2026 Sales Expectations